Wordt geladen...
Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance
Triple negative breast cancers (TNBC) without BRCA1/2 gene mutation or BRCAness are nowadays the breast malignancies most difficult to treat. Improvement of their treatment, for all phases of the disease, is an important unmet medical need. We analyzed the effect of homoharringtonine (HHT), a natura...
Bewaard in:
| Gepubliceerd in: | Am J Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
e-Century Publishing Corporation
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6556597/ https://ncbi.nlm.nih.gov/pubmed/31218111 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|